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Three experiments were conducted to determine:  the
type of plasminogen activator (PA) produced by cultured
ovine embryos; differences in PA profiles of uterine
flushings from pregnant and nonpregnant ewes; and the
effects of extracellular matrices and the PA system on
outgrowth of ovine inner cell masses (ICM).  In
Experiment 1, embryos were collected on days 7, 9 and 11
of pregnancy and cultured in alpha Miniumum Essential
Medium + 0.15% bovine serum albumin (MEM + BSA) until
equivalent gestational day (EGD) 15.  Samples of
conditioned medium were removed at 24-h intervals.
Determination of PA activity, using a caseinolytic assay,
revealed PA levels in the medium did not change up to EGD
12-13 but increased to peak levels by EGD 15.  Incubation
with anti-PA inhibitor-2 (PAI-2) increased PA activity
(P<0.05), and incubation with amiloride (AMR), a specific
Redacted for Privacyinhibitor of urokinase-type PA (uPA), reduced PA activity
(P<0.001) in the medium in a dose-dependent fashion.
Sodium dodecyl sulphate polyacrylamide gel
electrophoresis with zymography revealed a plasminogen­
dependent lytic zone (48-51 kD) within EGD 8-15 that was
eliminated in the presence of AMR and precipitated by
rabbit anti-bovine uPA.  A second plasminogen-dependent
lytic zone (79-83 kD) appeared after EGD 13.  In
Experiment 2, uterine flushings were obtained from
pregnant and nonpregnant ewes on days 7, 9 and 11.
Analysis by day revealed total protein concentration was
not different between days 7, 9 and 11 in nonpregnant
ewes, however, in pregnant ewes, total protein increased
dramatically (P<0.001) on day 11.  While plasmin
inhibitor (PI) activity steadily decreased (P<0.05),  PA
and plasminogen activator inhibitor (PAI) activity
remained constant in nonpregnant ewes.  In uterine
flushings from pregnant ewes, both PA and PAI activities
decreased (P<0.05) on day 11, while PI activities
remained unchanged.  Polyacrylamide gel electrophoresis
with zymography revealed the presence of 5 major
plasminogen-dependent lytic zones.  Day 11 pregnant
samples exhibited a 53 kD protein and a 60 kD inibitor
that were not present in any other samples.  Presence of
a 51 kD protein was consistently decreased in the
presence of amiloride in all samples, suggesting it may
be a uPA.  In Experiment 3, ICM were isolated from day7.5 embryos and cultured for 72 h on collagen,
fibronectin or laminin in MEM + 1.5% BSA containing one
of the following:  0 or 150 mg/m1 human plasminogen; 0 or
100 IU/ml PA inhibitor-2 (PAI-2); or 10% normal rabbit
serum or 10% rabbit anti-bovine uPA serum.  Area of
outgrowth was larger (P<0.01) in 0 µg /ml plasminogen than
in 150 mg/m1 plasminogen.  Fibronectin supported the
greatest outgrowth (P<0.001) and largest number of
migrating cells (P<0.001).  While addition of anti-uPA or
PAI-2 to the culture medium had no effect on outgrowth
area (P>0.10), fewer (P<0.05) cells migrated from ICM in
0 than 100 IU/ml PAI-2.  Inner cell masses on fibronectin
produced more (P<0.01) PA than on collagen or laminin,
however, PA production was not correlated with areas of
outgrowth (r=0.06; P>0.77) or cell numbers in the
outgrowths (r=0.02; P>0.90).  Results of these studies
suggest 1) ovine embryos produce an urokinase-type PA, 2)
total protein, PA, PAI and PI levels change with day and
pregnancy status and 3) while fibronectin enhances
cellular outgrowth from ovine ICM, however it is unlikely
that PA plays a functional role in this cellular
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INTRODUCTION
Plasminogen activators (PA) are serine proteases
that convert the serum zymogen plasminogen into plasmin,
the enyzme responsible for the degradation of fibrin and
turnover of the extracellular matrix (Christman et al.,
1977).  Two types of PA, each products of independent
genes, have been identified based on molecular mass and
functional differences: urokinase-type (uPA) and tissue-
type (tPA) with molecular masses of 30-55 and 70 kD,
respectively (Dano et al., 1985).  Proteolytic actions of
the PA/plasmin system are regulated by a family of serine
protease inhibitors.  These inhibitors are produced
primarily by endothelial cells, placenta and platelets
(Hart and Rehemtulla, 1987).  Plasminogen activators are
involved in a variety of reproductive processes including
ovulation (Beers et al., 1975), spermatogenesis (Lacroix
et al., 1977, 1981), trophoblastic invasiveness during
implantation (Strickland et al., 1976; Sherman et al.,
1976), parietal endoderm migration during embryogenEsis
(Strickland et al., 1976) and facilitation of hatching
(Menino and Williams, 1987).
Although PA is produced by a wide variety of embryos
(rats, Leidholm and Astedt, 1975; mice, Strickland et
al., 1976; swine, Mullins et al., 1980; cattle, Menino
and Williams, 1987; and sheep, Menino et al., 1989), the2 
exact role it plays in embryonic development is unclear.
Plasminogen activator has been implicated in cell
migration and tissue differentiative events in mouse and
swine embryos, however very little information regarding
PA and its inhibitors in ovine embryonic development is
available.  Therefore, the objectives of these studies
were to 1) characterize the type of PA produced by ovine
embryos, 2) evaluate PA and PA-inhibitor profiles in
uterine flushings from pregnant and nonpregnant ewes, and
3) to investigate the involvement of the PA system in the
outgrowth of ovine inner cell masses on a variety of
extracellular matrices.3 
REVIEW OF THE LITERATURE
CLASSIFICATION AND BIOCHEMISTRY OF PLASMINOGEN ACTIVATORS
Plasminogen activators (PA) are serine proteases
that convert the proenzyme plasminogen into the active
enzyme plasmin by hydrolysis of an arginine-valine
peptide bond (Dano et al., 1985; Lijnen and Collen,
1988).  Two types of PA have been characterized,
urokinase-type PA (uPA) and tissue-type PA (tPA).  These
two enzymes differ in their molecular weight and
functional and immunological properties.  Based on their
nucleotide sequences, it has been demonstrated that the
two types of PA are independent gene products.  Tissue-
type PA has been purified from various sources including
porcine heart, kidney and ovary, and human uterus and
plasma (Dano et al., 1985).  The protease is synthesized
as a single-chain polypeptide proenzyme (sc-tPA) with a
molecular mass of approximately 70 kD.  The sc-tPA
molecule is proteolytically modified to yield two
polypeptide chains held together by disulfide bonds (Hart
and Rehemtulla, 1988).  The two chain form (tc-tPA) is
the active enzyme and contains a small catalytic chain of
30 kD bound to a larger 40 kD chain.  The 40 kD chain
contains four structural domains: a "finger" domain which
resembles a region in fibronectin; an epidermal growth
factor (EGF) domain which shares homology with EGF and4 
two kringle domains (Hart and Rehemtulla, 1988).  The
only known protein substrate for tPA is plasminogen.
Tissue-type PA is a major regulator of fibrinolysis and
the finger domain and one of the kringle domains are
responsible for the interaction of tPA with fibrin.
Although tPA contains approximately 7% carbohydrate,
removal of this moiety by glycosidases does not alter
enzyme activity.  However, in the presence of
tunicamycin, tPA is not secreted from the cell suggesting
glycosylation is required for transport of the protein
out of the cell (Little et al., 1984).
Urokinase-type PA was first purified from human
urine but has since been found in human plasma and in
conditioned culture fluid of several types of cell lines
(Dano et al., 1985).  The enzyme is synthesized as a
single chain molecule (sc-uPA) which must undergo
proteolytic cleavage to yield an active disulfide linked
two-chain molecule (tc-uPA) containing a catalytic and
noncatalytic subunit.  Unlike tPA, the noncatalytic
region of uPA contains only the EGF domain and one
kringle domain, however, the catalytic region of uPA is
homologous with the 30 kD chain of tPA.  While tPA
functions in fibrinolysis, uPA appears to be involved in
cellular migration and tissue remodeling (Vassalli et
al., 1976).  Sappino and co-workers (1989) found uPA mRNA
in the invasive and migrating trophoblast cells of Day5 
5.5-8.5 mouse embryos.  Like trophoblast, tumors are
endowed with proliferative and migrating properties and
have the ability to invade neighboring tissues.
Transformed cell lines and tumors frequently produce uPA
and experimental evidence suggests that the enzyme is
essential to their invasive properties (Ossowski and
Reich, 1983).
By the specific hydrolysis of an arginine-valine
bond in its substrate plasminogen, uPA generates plasmin.
Plasmin has broad trypsin-like specificity hydrolyzing
lysine and arginine peptide bonds in several proteins,
including casein (Remmert and Cohen, 1949), and
immunoglobins (Christman et al., 1977).  Due to its broad
specificity, the generation of plasmin from plasminogen
could cause unwanted proteolysis unless regulated.  To
control the location of PA-related events, certain cells
express receptors specific for uPA that will bind either
the single chain or two-chain form of the enzyme.  The
receptor-PA complex can confer PA activity to the cell
surface and influence proteolysis in close proximity to
the cell.  The EGF domain on the noncatalytic chain of
uPA is responsible for the enyzme-receptor interaction.
Unlike uPA, no cell surface receptors for tPA have been
reported.  Because tPA is not associated with specific
cellular functions, it has been hypothesized that the
presence of receptors for tPA could interfere with the6 
primary function of the enzyme in fibrinolysis.
A low molecular weight form of uPA generated by
extracellular cleavage exists at 30 kD.  This molecule is
comprised of the catalytic subunit of uPA and a small
peptide of the non-catalytic subunit.  Although
enzymatically active, this low molecular weight species
of uPA does not bind to cellular receptors, and a
specific role in vivo is yet to be defined.
PLASMINOGEN ACTIVATOR INHIBITORS
The activities of PA in vascular and extracellular
spaces may be regulated in a variety of ways:  (a) by
hormonal regulation of their biosynthesis; (b) by
proteolytic conversion of single-chain PA into the two-
chain active form of the enzyme; (c) by interaction with
cell-surface receptors or with proteins that function as
cofactors in the activation of plasminogen; and (d) by
rapid clearance of PA via the liver.  Also important in
the regulation of PA activity are the serine protease
inhibitors (SERPINS), a family of glycoproteins that
covalently bind to and inhibit PA (Kruithof, 1988).  Four 
inhibitors of tPA and/or uPA have been identified:  PA 
inhibitor-1 (PAI-1); PA inhibitor-2 (PAI-2); PA 
inhibitor-3 (PAI-3); and protease nexin. 
Plasminogen activator inhibitor-1 is the major PAI
in plasma, and is derived from a variety of sources
including endothelial cells, platelets, placenta and the7 
conditioned media of fibrosarcoma cells and hepatocytes.
The inhibitor is a 52 kD glycoprotein which is capable of
reacting with the single chain form of tPA.  Plasminogen
activator inhibitor 1 is not a stable compound and
modification of its structure leads to spontaneous
inactivation.  Levels of PAI-1 are regulated by
glucocorticoids, endotoxins, interleukin-1, transforming
growth factor beta, tumor necrosis factor and thrombin.
Plasminogen activator inhibitor-2 is found in
several tissues including the trophoblastic epithelium of
the placenta, monocytes, leukocytes and fibrosarcoma
cells.  Unlike PAI-1, PAI-2 exists in two different
forms.  Intracellularly, PAI-2 exists as a
nonglycosylated molecule with a molecular mass of 47 kD.
The secreted form of PAI-2 is glycosylated and has a
molecular mass of 60 kD.  Although PAI-2 is capable of
reacting with both types of PA, it has a higher affinity
for uPA than tPA.  Unlike PAI-1, PAI-2 is a stable
inhibitor and it's biosynthesis and release are regulated
by endotoxin and phorbol esters.
Plasminogen activator inhibitor-3 is present in
human urine and plasma at a molecular mass of 51 kD.
Although its physiological role is unkown, PAI-3 reacts
with both tPA and the two-chain form of uPA.
Protease nexin is a glycoprotein of 47 kD which was
first identified in the medium of fibroblasts.  Unlike the8 
other PA inhibitors, protease nexin has a broad specificity
and is capable of inhibiting thrombin, trypsin, plasmin and
factor Xa.
EARLY EMBRYONIC DEVELOPMENT IN THE OVINE
Sheep are seasonally polyestrous and in the Northern
hemisphere, exhibit 17 day estrous cycles during the months
of September through January.  Onset of estrus is defined as
Day 0 and fertlization occurs on Day 1 in mated ewes.  The
fertilized ovum or zygote is surrounded by an acellular
glycoprotein matrix called the zona pellucida which provides
a protective covering during the first 8 days of
development.  Days 1-3 of development are characterized by a
series of successive mitotic cleavages until Day 4 when the
embryo reaches the morula stage and contains approximately
32-64 cells.  At this stage, the embryo enters the uterus
and begins to develop a fluid-filled cavity called the
blastocoel.  By Day 6, the blastocoel is enlarged, the
embryo contains 300 cells and the embryo is termed a
blastocyst.  At the blastocyst stage, the first cellular
differentiation occurs with the development of an outer
trophectoderm surrounding a core of inner cell mass (Herbet
and Graham, 1974; Denker, 1976).  On Day 8, endodermal cells
from the inner cell mass migrate along the blastocoelic side
of the trophectoderm and form the trophoblast (Wintenberger-
Torres and Flechon, 1974).  Migration of endoderm occurs
along an extracellular matrix containing among other9 
components, the glycoproteins type IV collagen, fibronectin
and laminin.  The inner cell mass will continue to
differentiate into the embryo proper while the trophoblast
will develop into the extraembryonic membranes of the
placenta.  Between Day 8 and 9, the embryo "hatches" and
sheds the zona pellucida.  The blastocyst continues to
expand and by Day 10, mesures 0.4-0.9 mm in diameter and
contains approximately 3000 cells (Wintenberger-Torres and
Flechon, 1974).  On day 11, the blastocyst begins elongating
and by Day 12, reaches a length of 10-22 cm.  By Day 15, the
embryo is a blastodermic vesicle which begins to make
contact with the uterine epithelium and on Day 16, contacts
between blastocyst and uterus are numerous (Boshier, 1969).
PLASMINOGEN ACTIVATOR IN MAMMALIAN EMBRYONIC DEVELOPMENT
RODENT EMBRYOS
In 1975, Leidholm and Astedt first detected the
presence of PA in the rat ovum.  Their study showed that Day
1-4 ova exhibited fibrinolytic activity which was diminished
in the presence of tranexamic acid, a competitive inhibitor
of PA.  By Day 6, when the ovum reached the uterus, the
fibrinolytic activity had disappeared.  Because proteolytic
activity of cells in culture prevents their adhesion to
surfaces and to each other, Leidholm and Astedt (1975)
hypothesized that a decrease in fibrinolytic activity of the
ovum may be a requirement for adhesion and implantation of
the embryo.10 
Strickland et al. (1976) investigated PA production by
mouse embryos.  Plasminogen activator was produced in a
biphasic manner and was first detectable on Day 6 of
pregnancy.  The first phase of PA production rose to maximum
levels by Day 8 and then decreased.  During the second
phase, a larger amount of the enzyme accumulated and levels
remained high until at least Day 15.  By isolating the
trophoblast and inner cell mass of the blastocyst,
Strickland et al. (1976) were able to assay these tissues
individually for PA production.  Trophoblast was responsible
for the first phase of enzyme synthesis, and the second
phase of production was due to the inner cell mass.
Sherman et al. (1976) reported similar PA profiles when
they isolated inner cell mass and trophoblast from Day 5 to
14 mouse embryos.  Results of their study showed that PA
production by the trophoblast appeared late on the fifth or
early on the sixth day of gestation, peaked between Day 7-9
and declined to low levels thereafter.  In contrast,
parietal endoderm cells of the inner cell mass began
producing PA on Day 7 and secreted increased amounts after
Day 8.
The invasive period of mouse embryos is between Days 6
and 10 of embryonic development.  This interval corresponds
with the period of PA secretion from the trophoblast and
suggests the enzyme may be involved in implantation.  By Day
7, the parietal endoderm completely covers the inner surface11 
of the trophectoderm, and has begun secreting Reichert's
membrane, the extracellular matrix between the endoderm and
trophectoderm.  In the studies by Sherman et al. (1976) and
Strickland et al. (1976) levels of PA from isolated inner
cell masses were detectable on Day 7, and synthesis of the
enzyme continued for as long as the cells were viable.
Thus, it appears inner cell mass may produce PA throughout
its life span.  Suggested roles for PA in the parietal
endoderm include facilitating migration along the
trophectoderm and involvement in the metabolism of
Reichert's membrane.
Bode and Dziadek (1979) investigated PA production
in both embryonic and extraembryonic mouse tissues.
Plasminogen activator secretion was initiated
progressively in different mouse embryo tissues during
development from the 7th to 10th day of gestation.  In
Day 7 embryos, the only tissues that produced PA were
parietal endoderm, extraembryonic ectoderm and
ectoplacental cone.  On Day 8, proliferation and
migration of mesodermal cells occurs.  Mesodermal PA
production was high during this period, providing further
evidence that this enzyme is associated with cell
migration.  Other tissues that begin secreting PA on Day
8 include embryonic ectoderm and visceral endoderm.  By
the 10th day of gestation, all tissues which were tested
secreted PA: parietal endoderm, amnion, visceral yolk sac12 
endoderm and mesoderm, and also tissue from the embryo
proper.  Bode and Dziadek (1979) concluded that although
it appears that PA may have different roles in different
tissues at different stages of development, the patterns
of its distribution are consistent with a role for this
enzyme in morphogenic movement.
Marotti et al. (1982) examined cultured parietal
endoderm, visceral endoderm and extraembryonic mesoderm
cells from Day 12 mouse embryos for the presence of PA.
Results indicated the presence of two types of PA at this
stage of embryonic development; parietal endoderm
produced tPA, while visceral and extraembryonic mesoderm
produced uPA.
Sappino et al. (1989) investigated the cellular
distribution of uPA and tPA mRNA during mouse oogenesis
and embryo implantation.  Over the years, evidence has
accumulated suggesting a role for proteases in the
ovulatory process (Espey, 1974; Beers et al., 1975).
Sappino's study isolated tPA mRNA and uPA mRNA in cells
from pre-ovulatory follicles.  These findings are in
agreement with a proteolytic role for PA in oogenesis and
ovulation.  Sappino et al. (1989) also located uPA mRNA
in the invasive trophoblast cells of Day 5.5-7.5 embryos,
providing further evidence for the involvement of PA in
implantation.13 
PORCINE EMBRYOS
Unlike mice and rats, porcine embryos do not have an
invasive form of implantation.  Instead, porcine embryos
exhibit placentation that involves interdigitation of
microvilli between the epithelial surfaces of the
trophoblast and endometrium.  Mullins et al. (1980)
undertook a study to investigate whether the absence of
invasive implantation within the porcine uterus is
possibly due to a failure of the conceptus to produce PA
or the presence of an inhibitor.  By isolating and
culturing porcine embryos in the early stages of
placentation (Day 12), Mullins et al. (1980) observed a
time-dependent increase in PA activity in the conditioned
medium.  After examination of uterine flushings collected
from Days 8-18 of pregnancy, Mullins et al. (1980) found
low PA activity, particularly after Day 12.  Because
embryos isolated at this time and subsequently cultured
in vitro secreted PA, Mullins et al.  (1980) hypothesized
that embryonic PA activity was suppressed in utero.
Plasminogen activator levels in uterine flushings of
gilts was also examined.  Mullins et al. (1980) found
high PA activity on Days 3 and 18 of the cycle, but much
lower levels at Days 12 and 15.  To determine whether
there is an inhibitor of PA during mid-cycle, samples of
Day 15 uterine flushings with negligible PA activity were
mixed with samples of Day 3 and Day 18 flushings.  The14 
results showed a significant decrease in PA activity of
Day 3 and 18 uterine flushings in the presence of Day 15
flushings, suggesting the presence of a mid-cycle
inhibitor.  To determine whether the inhibitor was
hormone induced, uterine flushings were obtained from
ovariectomized gilts maintained on either progesterone or
estrogen.  An assay for PA activity revealed low levels
of PA in progesterone-treated animals.  These results
indicated that the inhibitor was progesterone induced.
Further assays revealed that this progesterone-induced
inhibitor also reduced the release of PA from cultured
blastocysts in a concentration-dependent manner.  Because
porcine embryos are not invasive in uterine tissues, but
are invasive if transplanted to an ectopic site (Samuel,
1971), Mullins et al. (1980) concluded that the
progesterone-induced inhibitor may possibly play a role
in preventing invasive implantation.
Between Days 10-16, the porcine blastocyst elongates
from a small sphere to a long, thread-like form.  This
process occurs by means of cellular reorganization and
Fazleabas et al. (1983) observed PA release during this
period.  Similar to the findings of Strickland et al.
(1976) in mouse embryos, Fazleabas et al. (1983) also
observed that  PA production by porcine embryos was
biphasic.  The initial phase occured between Days 10-12
and paralleled the early elongation phase, while the15 
secondary phase occurred on Days 14-16 and coincided with
the time when increased DNA synthesis was occurring.
Fazleabas et al. (1983) found that between the two phases
of PA production (Days 12-13), the endometrium secreted
high levels of an inhibitor of plasmin into the uterine
lumen.  This inhibitor may serve to protect the uterus
against proteolysis by PA produced by the porcine
blastocyst.  Plasminogen activator produced by the
porcine blastocyst is apparently not associated with
implantation as is suggested for the mouse.  Instead, it
is associated with the period of intense tissue
remodeling and proliferation occurring during the
elongation phase of development.
BOVINE EMBRYOS
Menino and Williams (1987) were the first to
investigate PA production and its role in bovine
embryonic development.  Sixteen-cell to early morula
stage embryos were cultured in five concentrations of
plasminogen ranging from 0-120 µg /ml.  Plasminogen
activator production was low for the first 48 h of
culture, increased between 48-120 h, and plateaued
thereafter.  Percentages of embryos developing to the
intiating hatching blastocyst, hatched blastocyst,
attached blastocyst, and attached blastocyst with
trophoblastic outgrowth stages did not differ among the
five levels of plasminogen.  However, as plasminogen16 
concentration increased in the culture medium, initiation
and completion of hatching accelerated.  Initiation of
hatching ranged from 108.7-168.0 h and occurred during
the time when the blastocyst was rapidly increasing its
rate of plasminogen activation or the rate of activation
had just plateaued.  These results suggest that PA may
facilitate hatching, perhaps by weakening the zona
pellucida proteolytically so as to allow escape by the
expanding blastocyst.
Kaaekuahiwi and Menino (1990) evaluated the
relationship of PA production to cell stage, cell number
and changes in overall diameter and zona pellucida
thickness.  Total PA production was correlated positively
to embryonic size, developmental stage and cell number,
and negatively, but weakly, correlated to zona pellucida
thickness.  Hatched embryos produced more total PA than
embryos that did not hatch, supporting the hypothesis of
Menino and Williams (1987) that PA is involved in the
hatching process.
Dyk and Menino (1991) partially characterized the
tissue source and type of PA produced by Day 12-14 bovine
embryos.  Using sodium dodecyl sulphate-polyacrylamide
gel electrophoresis (PAGE) and zymography, light (41.5­
47.0 kD) and heavy (86.1-92.2kD) forms of PA were
detected.  Based on molecular mass classification, the
light form was classified as a uPA while the heavy form,17 
being too heavy for tPA, was suggested to be a complex
between uPA and a PAI.  When blastocyst tissues were
microdissected, Dyk and Menino (1991) found that the
principal source of PA production was the trophoblast and
not the embryonic disc.
Berg and Menino (1992) used antibodies against uPA
and tPA and amiloride, a competitive inhibitor of uPA, to
demonstrate that the light form of PA reported by Dyk and
Menino (1991) was indeed uPA and not tPA.  Treatment with
anti-uPA abolished PA activity whereas anti-tPA had no
effect on PA activity in embryonic samples suggesting
that Day 12-14 bovine embryos produce only uPA.  Addition
of amiloride to embryonic samples completely eliminated
PA activity, further confirming that Day 12-14 bovine
embryos produce only uPA.
OVINE EMBRYOS
The only report to date of PA production by ovine
embryos is from Menino et al. (1989).  In this study,
plasminogen activator production by ovine embryos and the
effects of plasminogen on ovine embryo development and
zona pellucida integrity were evaluated.  When compared
with embryos cultured in 0 µg /m1 plasminogen, more
blastocysts hatched in medium containing 60 and 120 µg /ml
plasminogen.  Zona pellucida solubility increased as
plasminogen concentration in the medium increased,
suggesting plasmin can alter zona pellucida integrity.18 
Plasminogen activator production was low until the morula
stage, increased during the morula-blastocyst transition
and remained elevated throughout blastocoelic expansion
and hatching.  This pattern of PA production may reflect
transcriptional and translational events that are
occurring during activation of the embryonic genome in
sheep.  Crosby et al. (1988) documented that the wave of
transcriptional activity associated with activation of
the ovine embryonic genome occurs during the fourth cell
cycle or the period preceding the 16-cell stage.
Plasminogen activator therefore may be one of the many
gene products induced during the transition from maternal
to embryonic control of early development.  Menino et al.
(1989) also reported that PA production and plasminogen
conversion to plasmin were poorly correlated with zona
pellucida solubility.  The results of this study
therefore indicated that although ovine embryos produce
plasminogen activator and plasmin can increase zona
pellucida solubility, other factors may also be involved
in altering zona pellucida integrity prior to hatching.19 
OVINE EMBRYOS PRODUCE AN
UROKINASE-TYPE PLASMINOGEN ACTIVATOR IN VITRO20 
ABSTRACT
The type of plasminogen activator (PA) produced by
cultured ovine embryos was partially characterized.  Day
7, 9 and 11 embryos were surgically collected from
estrous-synchronized, superovulated and handmated
crossbred ewes and cultured in alpha Minimum Essential
Medium containing 0.15% BSA for 8, 6 and 4 days,
respectively.  At 24-h intervals; medium was recovered
and frozen at -20°C and embryos were observed for
developmental stage.  Plasminogen activator
concentrations in the medium were determined by a
caseinolytic assay.  Characterization of the type of PA
produced by ovine embryos was conducted using SDS-PAGE
and zymography, amiloride, a competitive inhibitor of
urokinase-type PA (uPA), and antisera to human uPA (anti­
uPA), tissue-type PA (anti-tPA) and PA inhibitors 1
(anti-PAI-1) and 2 (anti-PAI-2).  Plasminogen activator
levels in the medium did not change up to equivalent
gestational days (EGD) 12-13 but increased to peak levels
by EGD 15.  Zymographic analysis revealed only one
plasminogen-dependent lytic zone (48-51 kD) within EGD 8­
13; however, a second plasminogen-dependent lytic zone
appeared after EGD 13 (79-83 kD).  When medium was
incubated with anti-uPA, anti-tPA or anti-PAI-1, no
differences (P>0.10) in PA activity were detected21 
compared to medium incubated with non-specific
immunoglobulins.  Plasminogen activator activity in the
medium increased as anti-PAI-2 increased (P<0.05) and
amiloride reduced PA activity (P<0.001) in a dose-
dependent fashion.  Ovine embryonic PA was succesfully
immunoprecipitated with anti-rabbit bovine uPA serum.
These data suggest that Day 7, 9 and 11 ovine embryos
produce a uPA (48-51 kD) and possibly a PAI-2-like
protein that complexes with the embryonic uPA and forms a
high molecular mass PA complex (79-83 kD).
INTRODUCTION
Plasminogen activators (PA) are serine proteases
responsible for converting the extracellular proenzyme
plasminogen into the active serine enzyme plasmin
(Christman et. al., 1977).  Two major forms of PA exist
that are characterized by molecular mass: urokinase-type
PA (uPA; 31-55 kD) and tissue-type PA (tPA; 70 kD)  (Dano
et al., 1985). Plasminogen activators are associated with
a variety of physiological processes including
fibrinolysis, ovulation, spermatogenesis, and
implantation (Strickland, 1980; Dano et al., 1985).
Tissue-type PA is the principal PA involved in clot
lysis whereas uPA is involved in cell migration (Dano et
al., 1985).  Embryonic production of PA has been
identified in a variety of species, including rats
(Leidholm and Astedt, 1975), mice (Sherman et al., 1976;22 
Strickland et al., 1976), swine (Mullins et al., 1980;
Fazleabas et al., 1983), cattle (Menino and Williams,
1987) and sheep (Menino et al., 1989), however, the
physiological role of PA in early development is not
well-defined.  In cattle embryos, PA production is
positively correlated with embryonic size, developmental
stage and cell number (Kaaekuahiwi and Menino, 1990).  In
sheep embryos, PA production increases during the morula
to blastocyst transition, and remains elevated through
blastocoelic expansion and hatching (Menino et al.,
1989).  Because tPA and uPA participate in different
physiologic processes, identifying the type of PA
produced may afford a better understanding of the
function of this enzyme in early embryogenesis.  Also,
because onset and maintenance of PA production appears to
be related to embryonic cell stage, it could be a useful
biochemical marker for investigating gene expression in
early embryos.  Therefore, to begin elucidating the role
of PA in development, the objective of this study was to
identify the type of PA produced by pre-attachment sheep
blastocysts.
MATERIALS AND METHODS
EMBRYO COLLECTION AND CULTURE
Twenty-five multiparous, Polypay ewes were estrous
synchronized with cloprostenol sodium (Estrumate; Haver;
Shawnee, KS) and superovulated with porcine follicle23 
stimulating hormone (pFSH; Schering-Plough Animal Health
Corp., Kenilworth, NJ).  Ewes received two 100 Ag i.m.
injections of cloprostenol sodium 9 days apart (Day 0 =
first cloprostenol sodium injection) and twice daily
injections of pFSH i.m. at dosages of 4, 3 and 2 mg on
days 8, 9 and 10, respectively, for a total of 18 mg per
ewe.  Estrus detection was initiated 24 h after the
second injection of cloprostenol sodium and ewes were
handmated by one of three rams starting at the onset of
estrus and thereafter at 12-h intervals for as long as
the ewe would accept the ram or for a total of at least 3
matings.  Embryos were surgically collected from mated
ewes 7, 9 or 11 days after onset of estrus.  Anesthesia
was induced in ewes by injection of 10 ml of 2.5%
thiamylal sodium (Biotal; Boehringer Ingelheim Animal
Health Inc.; St. Joseph, MO) into the jugular vein and
was maintained during surgery via inhalation of halothane
(Fluothane; Fort Dodge Laboratories Inc.; Fort Dodge, IA)
and oxygen.  The reproductive tract was exteriorized via
ventral midline laparotomy and uteri were flushed in
retrograde fashion with alpha Minimum Essential Medium
(MEM; Sigma Chemical Co., St. Louis, MO), buffered with
N'-2-hydroxyethyl piperazine-N'-ethanesulfonic acid
(HEPES; MEM+H; Sigma).  Flushings were examined with a
dissecting microscope and embryos were recovered by
aspiration.  Embryos were washed in 5-10 ml of MEM+H with24 
15 mg/ml bovine serum albumin (MEM+H+BSA; Sigma) and
transferred to screw-cap tissue culture tubes containing
10 ml of MEM+H+BSA maintained at 39°C.  Culture tubes
were transported to the laboratory and embryos were
recovered from the tubes and washed three times in 50-Al
microdrops of MEM+BSA.  Embryos were evaluated for cell
stage and overall morphology with an inverted-stage
phase-contrast microscope at 100-200x magnification.  Day
7, 9 and 11 embryos were cultured in 50, 75 or 125-Al
microdrops, respectively, of MEM+BSA under paraffin oil
(Fisher Scientific Co; Tustin, CA) in a humidified
atmosphere of 5% CO2 in air at 39°C, and were observed
daily for stage of development.  At 24-h intervals,
starting at 24-h of culture and continuing through to an
equivalent gestational age of 15 days, embryos were
either transferred to fresh microdrops and the medium
recovered (Day 7 embryos) or 50 and 75-Al aliquots of
medium were withdrawn and replaced with fresh medium (Day
9 and 11 embryos, respectively).
At the end of culture, embryos and conditioned
medium were recovered separately, placed in 1-ml snap cap
tubes and stored at -20°C until evaluated for PA
activity.  To correct for any medium constituents that
may contribute to the spontaneous activation of
plasminogen, medium without embryos incubated under
identical conditions was also recovered and frozen.25 
ELECTROPHORESIS AND ZYMOGRAPHY
To identify the type of PA produced by early sheep
embryos, one dimensional sodium dodecyl sulfate­
polyacrylamide gel electrophoresis (SDS-PAGE) under non-
reducing conditions and casein/plasminogen zymography
(Granelli-Piperno and Reich, 1978; Vassalli et al., 1984)
were conducted.  Conditioned medium was combined with an
equal volume of 2x SDS-PAGE sample buffer (5.0%; 20%
glycerol; 0.0025% bromophenol blue in 0.125M Tris HC1
buffer) and each polyacrylamide gel included lanes
containing a urokinase standard (American Diagnostica
Inc.; Greenwich, CT), and molecular mass markers ranging
from 14.4 to 97.4 kD (Bio-Rad Laboratories; Richmond,
CA).  Conditioned medium, urokinase standards and
molecular mass markers were aliquoted in 100 Al volumes
into castellated wells in a 4% acrylamide stacking gel
with 12% separating gel.  Each sample of conditioned
medium was analyzed in triplicate.  Following
electrophoresis, the polyacrylamide gels were gently
shaken in 2.5% Triton X-100 (Sigma) for 45 min., rinsed
with distilled water five times and shaken in phosphate
buffered saline (PBS) for 45 min.  The gel was removed
from the PBS, placed on plastic wrap, and excess PBS
removed by blotting gently with tissue paper.  A casein-
agar gel supported on a glass plate (zymograph) and
containing purified human plasminogen (Sigma) at a final26 
concentration of 20 µg /ml was placed on the
polyacrylamide gel.
Zymographs were prepared by combining equal volumes
of 2% nonfat dry milk (Carnation Co., Los Angeles, CA)
dissolved in buffer containing 0.0013M CaCl X 2H20, 0.10M
glycine, 0.038M Tris and 0.005M Na azide with a 2%
solution of melted agarose (Sigma) at 65°C.  Once the
solution cooled to 45°C, human plasminogen was added and
the mixture was cast onto a warmed glass plate and
allowed to cool.  Zymographs containing 0 µg /ml human
plasminogen were used for detection of any nonspecific
proteolytic activity.  Polyacrylamide gels with
zymographs were incubated at 39°C for 24-48 h and
observed approximately every 5 h for lysis.
Protease migration was determined during incubation
by measuring, to the nearest mm, the distance from the
edge of the separating gel to the center of the clear
caseinolytic bands in each lane.  To terminate the
incubation, zymographs were removed from the
polyacrylamide gels and fixed with 3.0% acetic acid for
15 min.  Zymographs were dried and stained for permanent
storage (Lowenstein and Ingild, 1976).  Polyacrylamide
gels were stained with 0.05% Coomassie Brilliant Blue
(Bio-Rad) in 65/25/10 water/isopropanol/acetic acid.  For
the amiloride experiments zymographs were prepared with
the following modifications: equal volumes of 2.2%27 
agarose and 2.2% nonfat dry milk were combined and 1 ml
containing either PBS or 100 mM amiloride (Sigma) and 200
Ag human plasminogen was added to 9 ml of the melt.  For
all zymographs, each caseinolytic zone in lanes
containing PA from conditioned medium, embryo tissues or
urokinase and tPA standards served as an observation.
Relative mobilities (Rm) of urokinase and tPA standards
and embryonic PA were calculated by dividing the distance
of migration from the point of origin on the separating
gel to the center of the caseinolytic zone on the
zymograph by the total length of the slab gel.  Molecular
masses of PA were determined by log molecular mass-Rm
plots derived from the standards.  Correlation-regression
calculations provided the equation of the line and the
correlation coefficients for the log molecular mass-Rm
plots (Steel and Torrie, 1980).  Unkown molecular masses
were calculated from the equation of the line.
IMMUNOPRECIPITATION
For immunoprecipitation, embryo tissues in SDS
solubilization buffer (Huarte et al., 1985) were used at
a final volume of 10 Al.  Embryo tissues were incubated
overnight at 4°C with 10 Al of either rabbit anti-bovine
uPA serum (American Diagnostica), or normal rabbit serum
(NRS) diluted 1:2 with PBS.  Thirty microliters of
Protein-G bearing Streptococcus cells (OMNISORB, Cal-
Biochem; La Jolla, CA) were added and the samples were28 
incubated for 2.5 h at room temperature.  Samples were
centrifuged using a microfuge (Beckman) for 5 min and the
supernatant was removed and combined 1:2 with 1X SDS-PAGE
sample buffer.  The pellet was rinsed three times with
100 Al of PBS and combined 1:1 with 2X SDS-PAGE sample
buffer.  Samples were electrophoresed and polyacrylamide
gels were overlaid with zymographs as previously
described.
PLASMINOGEN ACTIVATOR ASSAYS
Caseinolytic-agar gel assays as described by
Kaaekuahiwi and Menino (1990) were used to quantify PA
activity in the medium.  A modified caseinolytic assay
was also performed using amiloride and a panel of
antisera.  In the modified assay, 30 Al of pooled medium
from Day 7, 9 and 11 embryos were incubated with 15 Al of
goat immunoglobulins (IgG) raised against human PA
inhibitor-1 (anti-PAI-1), PAI-2 (anti-PAI-2), tPA (anti­
htPA) or uPA (anti-huPA) (American Diagnostica), non­
specific goat IgG (NSIgG; Sigma) or amiloride for 90 min
at 39°C.  Fifteen microliters of 240 µg /ml human
plasminogen were added to each sample and incubated at
39°C for 15 min.  Two, 25 Al aliquots of each reaction
mixture were pipetted in 4 mm diameter wells in the
casein agar plate and allowed to develop at room
temperature for 24 h.29 
STATISTICAL ANALYSIS
Differences in PA activities in the culture medium
were determined by analysis of variance and Duncan's
Multiple Range Test.  All analyses were conducted by
using the NCSS statistical software program (Number
Cruncher Statistical System, version 4.1, 1984, Hintze,
J.L., Kaysville, UT, USA).
RESULTS
One hundred thirty-three ova were recovered from 24
ewes with a mean ovulation rate of 11.8 ± 1.7 corpora
lutea.  Cell stages of embryos recovered on each of the
collection days are reported in table I-1.  Thirty-eight,
21 and 21 morphologically normal embryos were recovered
from ewes on days 7, 9 and 11, respectively.  Typically,
morulae to blastocysts were collected on Day 7,
blastocysts to hatched blastocysts on Day 9 and hatched
blastocysts on Day 11.  As shown in figure I-1, PA
activity in conditioned medium was unchanged until
equivalent gestational. day (EGD) 12-13 at which time
activity increased (P<0.05) reaching a peak at EGD 15.
Zymographic analysis of conditioned medium revealed
the presence of two plasminogen-dependent lytic zones
(figure 1-2).  The lighter molecular mass form (49.9 ±
0.5 kD) was present from EGD 7-15, however, the heavier
form (81.4 ± 1.2 kD) appeared from EGD 13-15 (table 1-2).
No suppression or enhancement of PA activity30 
(P>0.05) was observed after incubation of conditioned
medium with antisera for human uPA and tPA or PAI-1,
respectively (figure 1-3).  Increasing concentrations of
anti-PAI-2 in the reaction mixture increased (P<0.05) PA
activity (figure 1-3).  Incubation with amiloride reduced
(P<0.001) PA activity in the conditioned medium in a
dose-dependent fashion (figure 1-3).
Addition of amiloride to the zymographs completely
inhibited plasminogen-dependent caseinolysis by
conditioned medium at 49.9 kD and urokinase standards,
whereas caseinolysis by the tPA standards persisted
(figure 1-4).  As shown in figure 1-5, rabbit antiserum
for bovine uPA precipitated both the heavy and low
molecular mass forms of PA present in the ovine embryonic
samples whereas no caseinolysis was observed in samples
treated with NRS.
DISCUSSION
Results from the present study suggest that the PA
activity observed in early ovine embryos in a previous
report (Menino et al., 1989) is due to a uPA.
Zymographic analysis revealed that ovine embryos produced
a plasminogen-dependent protease (49.9 kD) during EGD 8­
15 and a second plasminogen-dependent band (81.4 kD)
during EGD 13-15.  The 49.9 kD species has many of the
characteristics of uPA and it is likely that the 81.4 kD
form is a uPA-PAI complex.  Several results support these31 
conclusions.  First, the molecular mass of the 49.9 kD
species corresponds to the values reported by Dano et al.
(1985) for uPA of 31-55 kD.  Second, PA activity
significantly decreased in dose-dependent fashion when
amiloride, a specific, competitive inhibitor of uPA
(Vassali and Belin, 1987), was added to the conditioned
medium.  Third, plasminogen-dependent caseinolysis by
ovine embryonic samples, but not tPA standards, was
reduced with the addition of this inhibitor to the
zymograph.  Fourth, antiserum to bovine uPA successfully
precipitated both forms of PA in the conditioned medium
and embryonic tissues.  Lastly, when antisera to PAI-2
was added to conditioned medium, PA activity increased.
Plasminogen activator inhibitor-2 is a more selective
inhibitor of uPA whereas PAI-1 has a higher binding
affinity for tPA (Hart and Rehemtulla, 1988).  An
increase in PA activity was not observed when anti-PAI-1
was added to embryonic samples.
Addition of either anti-htPA or anti-huPA had no
effect on sheep embryo PA activity.  Considering the
effect of amiloride, the observation that PA activity did
not change after anti-huPA was added to the embryonic
samples was unexpected.  Berg and Menino (1992) observed
complete suppression of PA activity in Day 12-14 cattle
embryonic extracts and conditioned medium with anti-huPA.
Sufficient antigenic differences must exist between the32 
cattle and sheep embryonic PA that prevent cross-
reactivity with anti-huPA.  However, there must also be
sufficient homology to allow for immunoprecipitation of
sheep embryonic PA with anti-bovine uPA.
Dano et. al. (1985) reported values for the
molecular mass of tPA of approximately 70 kD.  This value
is too low for the higher molecular mass band observed in
this study, and from the experimental evidence presented,
we propose that it may instead be a uPA complexed with a
PAI.  Three PAI have been purified, PAI-1, PAI-2, and
PAI-3.  All have the ability to form SDS-stable complexes
with PA that can be recognized zymographically (Kruithof,
1988).  The molecular masses of PAI range between 47-60
kD and when added to the molecular mass of the uPA band
results in a total mass similar, but somewhat higher than
that observed for the high molecular mass form of PA.
Typically, complexes between serine proteases and serine
protease inhibitors (serpins) are of lower molecular mass
than would be mathematically expected, due to release of
a cleavage fragment upon association.  Wiman and Collen
(1979) reported that dissociation of plasmin-a2­
antiplasmin complexes with NH4OH resulted in regeneration
of plasmin activity and an inhibitor with a lower
molecular mass (60 kD) than the uncomplexed inhibitor (70
kD).  The 81.4 kD band observed in our study is somewhat
consistent with the findings of Rehemtulla et al. (1987)33 
who observed an 85 kD complex between high molecular mass
uPA (52 kD) and a PA binding protein (33 kD) in human
bladder carcinoma cells.  Rehemtulla et al. (1990) also
observed a  72 kD PA in human K562 cells.  When
Rehemtulla et al. (1990) added excess of urokinase (52
kD) to the culture medium, the 72 kD band disappeared and
a 92 kD band appeared suggesting that the molecular mass
of the binding protein was 40 kD.  However, reverse
zymography revealed a PAI with a molecular mass of 45 kD.
Collectively, these findings suggest that upon
interacting with the PA, some portion of the PAI may be
cleaved, thus leaving a complex of lower molecular mass
than would be expected.
Similar to the results of this study, Dyk and Menino
(1991) reported that Day 12-14 cattle embryos also
produce two plasminogen-dependent lytic zones, a light
form of 41.5-47 kD and a heavy form of 86.1-92.2 kD. Berg
and Menino (1992) demonstrated that PA activity in Day
12-14 cattle embryos could be completely suppressed by
amiloride and anti-huPA whereas PA activity was unchanged
with anti-htPA, suggesting the heavy form observed by Dyk
and Menino (1991) was not a tPA.  Coates and Menino
(1991) demonstrated complete elimination of both the
heavy and light forms of PA in cattle embryos in
zymography containing amiloride, further supporting the
concept of an uPA-PAI complex comprising the heavy form.34 
The role PA plays in embryonic development is still
unclear.  However, Menino et al. (1989) demonstrated that
PA produced by ovine embryos increased zona pellucida
solubility in the presence of plasminogen thus effecting
a sublysis of the zona pellucida and facilitating
hatching.  Plasminogen activator has also been suggested
as having a role in cellular migration.  Studies by
Strickland et al.  (1976) demonstrated that blastocysts
secrete PA coincident with the time when trophoblast
cells become invasive.  Sappino et al. (1989) found uPA
mRNA in invasive and migrating trophoblast cells of Day
5.5 and 6.5 mouse embryos.  At Day 7.5, uPA mRNA was
localized in those trophoblast cells implanted deep in
the endometrium.  Another migratory event occurs when
parietal endoderm from the inner cell mass migrates along
the trophectoderm to line the blastocoel (Sherman et al.,
1976; Strickland et al., 1976).  The fact that parietal
endoderm begins secreting PA during this period suggests
this protease may play a role in cellular migration.
In summary, results of the present study have
demonstrated that ovine embryos produce a uPA and
possibly a uPA-PAI complex.  Further work is needed to
resolve the role of PA in early embryonic development and
the identity of the PAI-like molecule.35 
Figure I-1.  Plasminogen activator (PA) production by Day 7,
9 and 11 ovine embryos.  Day 7 embryos = 4,--e; Day 9
embryos = o---o; and Day 11 embryos = o- -o.
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Figure 1-2.  Zymographic analysis of conditioned medium from
ovine embryos collected on Day 7 of pregnancy, and cultured
for 192 h.  Numbers at top of figure indicate hours of
culture.
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Figure 1-3.  Plasminogen activator (PA) activity in ovine
embryonic samples following incubation with anti-tPA, anti­
uPA, amiloride, anti-PAI-1 or anti-PAI-2.
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Figure 1-4.  Zymographic analysis of ovine embryonic samples
in the presence or absence of amiloride, a competitive
inhibitor of urokinase-type plasminogen activator.  Ovine
embryonic samples, lanes 1 and 8; control medium samples,
lanes 2 and 7; tissue-type plasminogen activator standards,
lanes 3 and 6; and urokinase standard, lanes 4 and 5.
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Figure 1-5.  Immunoprecipitation and zymographic analysis of
ovine embryonic samples.  Anti-bovine uPA + PBS, lane 1 and
6; NRS + PBS, lane 2 and 7; ovine embryonic sample + NRS,
lane 3 and 8, ovine embryonic sample + anti-bovine uPA, lane
4 and 9, ovine embryonic sample + PBS, lane 5 and 10.
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21 Table I-1.  Cell stage of embryos recovered surgically from
ewes on days 7, 9 and 11 of pregnancy.
Developmental stages
Day of
pregnancy  D UFO C M EBL BL  X  I H
7  0  2  2  9 19 10 0 0 0
9  4 20 6 0 0  3 1 3 16
11  1 15 0  0  0  0 0 0 22
a Developmental stages are abbreviated as:  degenerate  (D),
unfertilized (UFO), cleavage stage (C), morula (M), early
blastocyst (EBL), blastocyst (BL), expanded blastocyst (X),
hatching blastocyst (I) and hatched blastocyst (H).41 
Table 1-2.  Molecular masses (kD) of plasminogen
activators produced by days 7,9 and 11 ovine embryos.
Molecular Mass (kD)
Form  n  Mean  SE
Heavy  8  81.4  1.2
Light  37  49.9  0.542 
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DIFFERENCES IN PLASMINOGEN ACTIVATOR,
PLASMINOGEN ACTIVATOR INHIBITOR AND PLASMIN
INHIBITOR IN UTERINE FLUSHINGS FROM
PREGNANT AND NONPREGNANT EWES46 
ABSTRACT
Uterine flushings (UTF) were examined for
differences in relative amounts of total protein,
plasminogen activator (PA), PA inhibitors (PAI) and
plasmin inhibitors (PI).  Uterine flushings (UTF) were
surgically collected on Days 7, 9 and 11 from estrous
synchronized, pregnant (P) and nonpregnant (NP) ewes.
Recovered UTF were concentrated by ultrafiltration and
total protein was determined using the Bio-Rad protein
assay.  Plasminogen activator, PAI and PI activities were
quantified using a caseinolytic assay.  Sodium dodecyl
sulfate polyacrylamide gel electrophoresis with
zymography was performed to analyze molecular masses of
PA activators and inhibitors present in UTF.  Analysis by
day revealed total protein concentration was not
different between Days 7, 9 and 11 in UTF from NP ewes,
however in UTF from P ewes, total protein increased
dramatically (P<0.001) on Day 11.  Although PA and PAI
activity remained constant in UTF from NP ewes, PI
activity steadily decreased (P<0.05) reaching low levels
on Day 11.  While PI activities did not change in UTF
from P ewes, both PA and PAI activities decreased
(P<0.05) on Day 11.  Polyacrylamide gel electrophoresis
with zymography revealed 5 major plasminogen-dependent
lytic zones.  When amiloride was added to zymographs,47 
activity in the 51 kD protein was depressed in all days
and was not dependent on pregnancy status.  Presence of a
53 kD protein and a 60 kD inhibitor was only detected in
UTF from P ewes on Day 11.  These results suggest: 1)
total protein levels in UTF increase with stage of
pregnancy; 2) levels of PA, PI and PAI fluctuate based on
day and pregnancy status and 3) five major molecular mass
classes of plasminogen-dependent proteins are present in
ovine UTF possibly including a urokinase-type PA (51 kD)
and a Day 11 pregnancy-specific protease (53 kD).
INTRODUCTION
Uterine luminal fluid (UTF) and its constituents
play a major role during early embryonic development.  A
variety of proteases and protease inhibitors have been
found in the uterine lumen.  Katz et al. (1976) reported
the presence of an estrogen-dependent trypsin-like
protease in the rat uterus which they classified as a
plasminogen activator (PA).  Dabitch and Owens (1978)
demonstrated that levels of a trypsin-like inhibitor were
high in uterine secretions from Day 6 pregnant mice.
Similarly, Fazleabas et al. (1982)  observed a
progesterone-induced protease inhibitor in the uterine
secretions of pregnant pigs.
The serine protease plasmin is the active product of
cleavage of the zymogen, plasminogen, by PA.  Plasminogen
activators can be classified into two types based on48 
molecular mass; urokinase-type PA (uPA, 30-55 kD), and
tissue-type PA (tPA, 70 kD).  Based on its proteolytic
capabilities, a role for PA is in the degradative
processes of tissue remodeling and reorganization of
extracellular structures.  In early embryonic
development, examples of intense tissue remodeling occur
with the differentiation and migration of developing
tissues within the blastocyst and during implantation of
the embryo into the endometrium (Strickland, 1980).
During the period of invasive implantation in mice,
increased levels of PA are associated with the
trophoblast, suggesting a correlation between this enzyme
and implantation (Strickland et al., 1976).  In contrast,
the uterus of the pig secretes high levels of a protease
inhibitor during this comparative stage of development
(Mullins et al., 1980).  Unlike the mouse, swine embryos
do not invasively implant, therefore, the presence
of the protease inhibitor may serve to protect the uterus
from unwanted proteolysis by the blastocyst.
Plasminogen activator production and plasminogen
conversion to plasmin increases during blastocoelic
expansion and hatching in sheep embryos (Menino et al.,
1989).  To date, no information regarding this protease
or its inhibitors in the UTF of sheep has been reported.
Therefore, the purpose of this study was to investigate
UTF from ewes for the presence of PA and related49 
inhibitors and determine if differences in these
parameters existed due to stage of pregnancy.
MATERIALS AND METHODS
COLLECTION OF UTERINE FLUSHINGS
Twenty multiparous Polypay ewes were randomly
assigned to pregnant (P) or nonpregnant (NP)  groups and
were estrous synchronized with two, 100 Ag i.m.
injections of cloprostenol sodium (Estrumate; Haver;
Shawnee, KS), given 9 days apart (Day 0 = first
cloprostenol sodium injection).  Those ewes assigned to
pregnant groups were superovulated with twice daily i.m.
injections of porcine follicle stimulating hormone (pFSH;
Schering-Plough Animal Health Corp., Kenilworth, NJ) at
dosages of 4, 3 and 2 mg on Days 8, 9 and 10,
respectively.  Estrus detection was initiated 24 h after
the second injection of cloprostenol sodium, and
continued at 12-h intervals.  All ewes were exposed to an
intact ram to detect estrus, but only superovulated ewes
were allowed to be handmated.  Seven, 9 and 11 days after
onset of estrus, ewes were anesthetized by injection of
10 ml of 2.5% thiamylal sodium (Bio-tal; Boehringer
Ingelheim Animal Health, Inc.; St. Joseph, MO) into the
jugular vein and maintained via inhalation with halothane
(Flouthane, Fort Dodge, Inc.; Fort Dodge, IA) and oxygen.
The reproductive tract was exteriorized via ventral
midline laparotomy and uteri were flushed in a retrograde50 
fashion with 60 ml of alpha Minimum Essential Medium
(MEM; Sigma Chemical Co., St. Louis, MO) buffered with
N'-2-hydroxyethyl piperazine-N'-ethanesulfonic acid
(HEPES/MEM+H; Sigma).  Flushings from both P and NP ewes
were examined with a dissecting microscope (10-40x) and
embryos recovered from P ewes were used for an ongoing
culture experiment.  Uterine flushings from all ewes were
centrifuged at 5,000 x g for 10 min at room temperature.
The pellet was discarded and the supernatant was stored
at -20°C.
ULTRAFILTRATION AND TOTAL PROTEIN DETERMINATION
Uterine flushings were thawed and concentrated to 3­
5 ml using a stirred ultrafiltration cell with a YM2
membrane (1,000 D molecular weight cut-off; Amicon
Corporation; Danvers, MA).  The retentate was stored at ­
20°C.
Protein concentrations in UTF were determined using
the Bio-Rad protein assay (Bio-Rad Laboratories;
Richmond, CA).  Standard curves were constructed using 0,
200, 400, 600, 800 and 1000 µg /ml BSA (Sigma).  Protein
concentrations of UTF were calculated using the equation
of the line for the standard curve.  Each UTF was assayed
in triplicate.
ELECTROPHORESIS AND ZYMOGRAPHY
One dimensional sodium dodecyl sulfate­
polyacrylamide gel electrophoresis (SDS-PAGE) was51 
conducted under nonreducing conditions with
casein/plasminogen zymography (Granelli-Piperno and
Reich, 1978; Vassali et al., 1984).  Twenty-five
microliters of concentrated UTF was combined with 75g1 of
1X SDS-PAGE sample buffer (2.5% SDS; 10% glycerol;
0.00012% bromophenol blue in 0.125 M Tris HC1 buffer) and
each polyacrylamide gel included lanes containing a
urokinase standard (E.C. 3.4.21.31; American Diagnostica
Inc; Greenwich, CT), and molecular mass markers ranging
from 14.4 kD to 97.4 kD (Bio-Rad).  Concentrated UTF,
urokinase standards and molecular mass markers were
aliquoted in 100 gl volumes into castellated wells in a
4% acrylamide stacking gel with a 12% separating gel.
Following electrophoresis, the polyacrylamide gels were
gently shaken in 2.5% Triton X-100 (Sigma) for 45 min,
rinsed with distilled water five times and shaken in
phosphate buffered saline (PBS) for 45 min.  The gel was
removed from the PBS, placed on plastic wrap, and excess
PBS removed by blotting gently with tissue paper.  A
casein-agar gel supported on a glass plate (zymograph)
and containing 20 gg/ml human plasminogen, was placed on
the polyacrylamide gel.  Zymographs were prepared by
combining equal volumes of 4% nonfat dry milk (Carnation
Co.; Los Angeles, CA), dissolved in buffer containing
0.0013 M CaC12 x 2H20, 0.10 M glycine, 0.038 M tris and
0.005 M sodium azide with a 2% solution of melted agarose52 
(Sigma) at 65°C.  Once the solution had cooled to 45°C,
human plasminogen was added.  The mixture was then cast
onto a warmed glass plate and allowed to cool.
Zymographs containing 0 mg/m1 human plasminogen were used
for detection of any nonspecific proteolytic activity.
Polyacrylamide gels with zymographs were incubated at
39°C for 24-48 h and observed every 5 h for lysis.  To
terminate the incubation, zymographs were removed from
the polyacrylamide gels and fixed with 3.0% acetic acid
for 15 min.  Zymographs were dried and stained for
permanent storage (Lowenstein and Ingild, 1976).
Polyacrylamide gels were stained as described by Dyk and
Menino (1991).  For the amiloride zymographs, UTF were
electrophoresed as previously described, and the
zymographs were prepared with the following
modifications: equal volumes of 2.2% agarose + 4.2%
nonfat dry milk were combined; 1 ml of either PBS or 100
mM amiloride (Sigma) and human plasminogen to a final
concentration of 20 µg /ml were added to 9 ml of the
agarose-nonfat dry milk mixture.  The zymograph was
allowed to cool and placed on the polyacrylamide gel.
For all zymographs, measurements and calculations were
made as described by Dyk and Menino (1991).
ASSAYS FOR PLASMINOGEN ACTIVATOR, PLASMINOGEN ACTIVATOR
INHIBITOR (PAI) AND PLASMIN INHIBITOR (PI)
The caseinolytic assay as described by Kaaekuahiwi
and Menino (1990) was used to determine PA levels in UTF.53 
To investigate levels of PAI and PI in UTF, modifications
of this technique were used.  Briefly, for both assays,
casein-agar plates were prepared as described by
Kaaekuahiwi and Menino (1991).  For the PAI assay, 45 gl
of UTF sample or MEM control were incubated for 30 min
with 30 gl of 10 IU/ml urokinase or PBS.  Fifteen
microliters of 360 gg/ml plasminogen was then added, and
the samples were allowed to incubate for an additional 15
min at 39°C.  Three 25 gl aliquots from each sample were
then pipetted into wells in the casein-agar plates and
allowed to develop at room temperature for 24 h.  For the
PI assay, 60 gl of 900 units human plasmin (E.C.
3.4.21.7; Sigma) were incubated with 30 gl of UTF sample
or MEM for 15 min at 39°C.  Three 25 gl aliquots from
each sample were pipetted onto the plates and allowed to
develop as described above.  The assay was terminated by
fixing the plates with 3% acetic acid for 15 min.  After
rinsing with tap water, areas of lysis were measured with
an electronic digital caliper.  A lytic zone area of 1
mm2 was equal to 1 protease unit and the inhibition of 1
protease unit was equal to 1 PAI unit (PAIU) or 1 PI unit
(PIU).  Calculations for inhibitor activities in UTF were
performed using the following equations derived from
Leprince et al. (1989):  1) total inhibitor (PAI/PI) =
[(area of 10 IU/ml urokinase - area of 0 IU/ml urokinase)
- (area of 10 IU/ml urokinase with conditioned medium ­54 
area of conditioned medium)];  2) plasmin inhibitor (PI)
= (area of PBS/control medium with plasmin standard ­
area of conditioned medium with plasmin standard); and 3)
PAI = (PAI/PI) - (PI).
DENSITOMETRIC ANANLYSIS
Zymographs were densitometrically scanned using a
model 1650 Transmittance/Reflectance Scanning
Densitometer (Bio-RAD) and scans were plotted using the
GS 350H software system (Hoefer Scientific Instruments,
San Fransisco, CA).  A compensating polar planimeter
(model L-20-M; LASICO; Los Angeles, CA) was used to trace
the densitometric scans and determine areas of the lytic
zones.  Areas of the lytic zones were expressed as
relative percentages of the entire densitometric scan.
STATISTICAL ANALYSIS
Total protein, activities of PA, PAI and PI in gg
total protein, concentration of PA, PAI and PI and
relative percentages of plasminogen-dependent lytic zones
were analyzed using multi-way analysis of variance.
Differences due to day, amiloride or pregnancy status
were analyzed using Duncans multiple range test.  All
analyses were conducted using the NCSS statistical
software program (Number Cruncher Statistical Systerm,
version 4.1, 1984, Hintze, J.L., Kaysville, UT, USA).
RESULTS
Total protein in UTF from Day 7,  9 and 11 P and NP55 
ewes is shown in Figure II-1.  Day of the estrous cycle
had no effect on total protein in NP ewes, however, after
remaining constant between Days 7 and 9, levels increased
dramatically (P<0.001) on Day 11 of pregnancy.  Although
protein levels on Day 11 of pregnancy appear higher than
on Day 11 of the estrous cycle, no significant
differences (P>0.05) were observed for pregnancy status.
Figure 11-2 shows PA activities based on day and
pregnancy status.  Plasminogen activator activities in
UTF from nonpregnant ewes were not different (P>0.05) by
day of the estrous cycle.  Although not different from
Day 9, PA in UTF from Day 7 of pregnancy was
significantly higher (P<0.05) than on Day 11.
While levels of PI remained constant, levels of PAI
were lower (P<0.05) on Day 11 than on Day 7 or 9 in UTF
from P ewes (Figure 11-3).  Although, PAI activity in UTF
from NP ewes was not different by day, PAI activity was
lower (P<0.05) on Day 7 and higher (P<0.05) on Day 11
when compared to respective UTF from P ewes. Plasmin
inhibitor activities in UTF from NP ewes steadily
decreased (P<0.05) each day, reaching lowest levels on
Day 11.
Table II-1 reports concentrations of PA, PAI and PI
in UTF collected from P and NP ewes.  Plasminogen
activator concentrations were lowest (P<0.05) in Day 11 P
UTF.  The only differences in PAI and PI concentrations56 
were due to pregnancy status with levels on Day 11 and
Day 7, respectively, being lower (P<0.05) in samples from
pregnant than from nonpregnant ewes.
Zymographic analysis revealed 5 major molecular mass
classes of plasminogen dependent-lytic zones (Figure II­
4).  Absence of plasminogen in zymographs failed to
support any caseinolysis, therefore confirming the
absence of nonspecific proteases.  Samples from Day 11 P
ewes also exhibited a PAI or PI that was was not observed
in other samples from P or NP ewes.  Relative percents of
the 5 major plasminogen-dependent lytic zones are
reported in Table 11-2.  Amiloride treatment depressed PA
activity in the 51 kD protein, however, a significant
reduction in relative percentage was observed only in
samples from Day 7 P ewes.  Amiloride treatment also
shifted the relative percentages of the 77 kD protein in
Day 11 P and the 47 kD protein in Day 7 NP and Day 9 P
ewes.  Differences in relative percentages by pregnancy
were observed in the 77 kD band for Days 7 and 9 and the
53 kD band was detected only in Day 11 P ewes (P<0.10).
The relative percentage of the 47 kD band was greater
(P<0.10) in samples from Day 9 P ewes but less (P<0.10)
in samples from Day 11 P ewes when compared to
corresponding samples from NP ewes.  Relative percentages
of the bands also varied by day of collection.  Day 9 NP
had greater (P<0.05) relative percentages of the 97 kD57 
and 77 kD bands than Day 11 but lower (P<0.05) relative
percentages of the 47 kD band than either Day 7 NP or Day
11 NP ewes.  The 77 and 47 kD bands were greater (P<0.05)
in Day 9 P ewes compared to Day 11 P ewes.
DISCUSSION
Total protein levels in UTF from P and NP ewes were
similar to those reported by Segerson (1981).  Values
increased dramatically on Day 11 of pregnancy, after
remaining fairly constant between Days 7 and 9.  In the
pig uterus, levels of protein in UTF do not differ
between P and NP animals until about Day 11 (Geisert et
al., 1982).  At this time, conceptuses induce release of
secretory vesicles from glandular epithelial cells.
Although not significantly different, total protein
levels in Day 11 P UTF in the present study were higher
than in samples from Day 11 NP ewes.
Although PA activities remained unchanged in NP
ewes, PA activity in Day 7 P ewes were higher than in Day
11 animals.  One explanation for this could be that ewes
which represented Day 7 P UTF were carrying 18 embryos at
the time samples were collected.  Menino et al. (1989)
reported ovine embryos secrete PA during the morula­
blastocyst transition which corresponds to approximately
Day 6 of embryonic development in sheep.  The presence of
18 embryos in the uterus could potentially lead to high
amounts of PA in the uterine lumen.  Another explanation58 
is the presence of the inhibitor in Day 11 P ewe UTF.
Although in this study the zymographs did not
discriminate between PAI or PI, the presence of either
would have depressed interpretable PA activity.  The
caseinolytic assay is an indirect assay that quantifies
PA activity relative to the amount of plasmin generated.
Therefore, either a PAI or PI would cause the measured PA
activity to be reduced. When evaluating PA activities,
however, one must consider that activities were expressed
relative to mg of total protein.  Because protein levels
were higher on Day 11 of pregnancy, the relative amount
of protein actually due to PA is, as a result,
mathematically lower.  The fluctuations observed in PAI
and PI activity no doubt represent changes in protein
composition in UTF.
Five major molecular mass classes of PA were
revealed by zymography.  No activity was present in
zymographs containing 0 µg /ml plasminogen indicating all
lytic zones were due to plasminogen-dependent
caseinolysis.  Additon of amiloride, a competitive
inhibitor of urokinase-type PA (uPA) to the zymographs
shifted activity in the 47, 51 and 77 kD proteins.
Although not significant, activities in the 51 kD protein
were consistently lower in the presence of amiloride.
Caution must be exercised in interpreting the changes in
relative percentages because elimination or reduction in59 
one protein would shift the relative percentages of other
proteins upward.  Because activity of the 51 kD protein
was lower or completely diminished in the presence of
amiloride, a shift in the relative percentage of the
remaining bands occurred.  This may account for the
increases observed in the 77 kD band in Day 11 P ewe UTF
and the 47 kD protein in Day 7 NP ewe UTF in the presence
of amiloride.  The fact that amiloride caused a
consistent suppression of the 51 kD protein suggests that
this band may be a uPA.  The observed molecular mass of
uPA ranges from 30-55 kD (Dano et al., 1985), further
suggesting this protein may be a uPA.
Two Day 11 P specific proteins were observed
zymographically.  One was a 53 kD protein and the second,
a 60 kD inhibitor.  Mullins et al. (1980) reported the
presence of a progesterone-induced inhibitor of PA in
Day-15 swine UTF.  Mullins et al. (1980) suggested that
the inhibitor may play a role in preventing invasive
implantation in the pig.  While the sheep, like the pig
does not exhibit invasive implantation, it is unclear
whether the inhibitor present in sheep UTF plays a
similar preventative role. Further studies on the
characteristics of this Day-11 P specific inhibitor need
to be undertaken before conclusions can be made about the
inhibitor's specific function.
Uterine proteins may play a variety of roles in60 
embryonic development.  Secretions of a number of
progesterone responsive proteins have been reported, some
of which appear to play a nutritional role (Roberts and
Bazer, 1988).  Other functions of uterine proteins may
include immunoprotective or antiviral functions.  The
present study reports activities of PA, PAI and PI in UTF
from P and NP ewes and also reports the presence of a
pregnancy-specific PA and inhibitor.  Further studies
need to be undertaken to investigate a role for these
proteins in early embryonic development.61 
Figure II-1.  Total protein in uterine flushings from Day
7, 9 and 11 pregnant and nonpregnant ewes.
a,b Values without common letters are different (P<0.05).
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Figure 11-2.  Plasminogen activator activities in uterine
flushings from Day 7, 9 and 11 pregnant and nonpregnant
ewes.
*Different from corresponding pregnant sample (P<0.05).
a,b Values without common letters are different (P<0.05).
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Figure 11-3.  Plasminogen activator inhibitor (PAI) and
plasmin inhibitor (PI) acivities in uterine flushings
from Day 7,  9 and
11 pregnant and nonpregnant ewes.
*Different from corresponding pregnant sample.
a,b,c Values without common letters are different
(P<.05).
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Figure 11-4.  Zymographic analysis of uterine flushings in
the presence (a) or absence (b) of amiloride from pregnant
and nonpregnant ewes.  Lane 1, Day 7 pregnant, Lane 2 Day 7
nonpregnant, Lane 3, Day 9 pregnant, Lane 4, Day 9
nonpregnant, Lane 5 Day 11 pregnant, Lane 6 Day 11
nonpregnant.
411//1 mow am, 
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,41111111. 
b Table II-1.  Concentrations of plasminogen activator (PA), plasminogen
activator inhibitor (PAI) and plasmin inhibitor (PI) in uterine
flushings collected from pregnant (P) and nonpregnant (NP)  ewes.
Day of collection and pregnancy status
7P  7NP  9P  9NP  11P  11NP  EMSc
PA
IU/ml  2.02a  0.16  0.61a ,b  0.24  0.07b*  0.76  0.69
PAI
InU/A1  171.5  76.1  172.5  140.1  68.5*  179.0  5103.8
PI
InU/A1  26.2*  113.7  69.7  84.4  135.5  92.0  3131.4
n 2  2 6  2 5 2
* Different from corresponding nonpregnant sample (P<0.05)
a,b Values with different subscripts differ from corresponding
days of collection (P<0.05).
c Error mean squareTable 11-2.  Relative percentages of major molecular mass classes of plasminogen
activators in uterine flushings collected from pregnant and nonpregnant ewes 7, 9
and 11 days after onset of estrus.
- amiloride  + amiloride
Molecular Pooled
mass (kD)  7NP  7P  9NP 9P  1INP  IIP  7NP  7P  9NP  9P  1INP  lip  SE
97 + 0.4 18.8a,6  10.8a  30.06  21.8a  15.5a  14.8a  20.2a  35.06  24.8a  17.0a  18.8a  4.0 29.9a,b
77 + 0.3  40.01  46.00,6  68.21  48.06  41.0a  33.8:  39.81  49.8a  65.0t+  49.8a  40.5a  49.0a  4.0
53 + 0.0  0.0  0.0a  0.0 0.0a  0.0+  28.26  0.0  0 0  0.0  0.0a  0.0++  32.06  4.8
' a
51 + 0.5  11.50  25.8:* 7.8a  23.5,  0.0  0.0  0.0a  0.0  5.6 8.8a  0.0a  9.8a  0.0a
*
47 + 0.3 0.0t  19.86  21.0++  0.0  17.5  10.2 9.8a  5.9a  0.0t+  10.5  19.2t+  2.2
a a a  a
** Different from corresponding amiloride treated sample (P(0.05)
*  Different from corresponding amiloride treated sample (P<0.10)
++ Different from corresponding pregnant sample (P(0.05)
+  Different from corresponding pregnant sample (P <0.10)
a,b,cPercentages with different subscripts differ from corresponding days of-collection (P(0.05)67 
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EVALUATION OF EXTRACELLULAR MATRICES
AND THE PLASMINOGEN ACTIVATOR SYSTEM IN OVINE
INNER CELL MASS OUTGROWTH IN VITRO70 
ABSTRACT
Effects of extracellular matrices (ECM) and the role
of the plasminogen activator (PA) system in outgrowth of
ovine inner cell masses (ICM) in vitro were investigated.
Inner cells masses were isolated by immunosurgery from
Day 7.5 embryos and cultured for 72 h in alpha Mininum
Essential Medium with 15 mg/ml BSA on ECM of collagen,
fibronectin or laminin.  At 24-h intervals, areas of the
ICM and outgrowth were measured and the numbers of
migrating cells were counted.  Experiment 1 evaluated the
effects of plasminogen (PGN) and ECM-type on ICM
outgrowth.  Inner cell masses were cultured in ECM-
coated, glass Lab-Tek chamber slides in medium containing
0 or 150 µg /ml human PGN.  Experiment 2 evaluated the
effects of 100 IU/ml PA inhibitor-2 (PAI-2) or 10% rabbit
antiserum to bovine urokinase-type PA (anti-uPA)  on ICM
outgrowth in fibronectin-coated, glass Lab-Tek slides.
Experiment 3 evaluated the relationship between PA
production and ECM-type on ICM outgrowth.  Inner cell
masses were cultured in 25-Al microdrops under paraffin
oil on ECM-coated 60 x 15 mm plastic culture plates.  In
Experiment 1, ICM in 0 µg /ml PGN had a larger (P<0.01)
mean area of outgrowth than in 150 µg /ml PGN.
Fibronectin supported greater (P<0.001) numbers of
migrating cells than did either collagen or laminin.  In
Experiment 2, addition of anti-uPA or PAI-2 to the71 
culture medium had no effect on outgrowth area (P>0.10).
However, whereas the numbers of migrating cells in anti­
uPA did not differ compared to normal rabbit serum, fewer
(P<0.001) cells migrated from ICM in 0 than in 100 IU/ml
PAI-2.  In Experiment 3, ICM on fibronectin produced more
(P<0.01) PA than on collagen or laminin, however, PA
production was not correlated with areas of ICM
outgrowths (r=0.06;P>0.77) or cell numbers in the
outgrowths (r=0.02; P>0.90).  Inner cell mass area was
correlated with PA production (r=0.41; P<0.01).  These
results suggest that fibronectin enhances cellular
outgrowth from ovine inner cell masses, however, it is
unlikely that PA plays much of a functional role in this
cellular migration.
INTRODUCTION
Plasminogen activators (PA) are serine proteases
that convert the zymogen plasminogen into plasmin, the
enzyme active in clot lysis (Cristman et. al., 1977).
Reproductive processes PA are involved in include
ovulation (Dano et al., 1985), blastocyst escape from the
zona pellucida (Menino et al., 1989), and implantation
(Dano et al., 1985). Strickland et al. (1976) have
suggested that PA may be involved in the tissue
remodeling and cellular proliferation occurring in early
embryogenesis.  Evidence supporting this concept in other
systems has been demonstrated in that high levels of PA72 
are associated with migrating tumor cells (Dano et al.,
1985) and the epithelium of mammary glands undergoing
involution (Ossowski et al., 1979).  Embryonic PA
production has been identified in several species and is
produced in a biphasic manner by mouse and swine embryos
(Sherman et. al., 1976; Fazleabas et. al., 1983; Menino
and Williams, 1987; Menino et al., 1989).  In mouse
embryos, the first phase of PA production is by the
trophoblast and is believed to be involved in
implantation. The second phase is attributed to parietal
endoderm and is possibly involved in cellular migration
(Sherman et. al., 1976; Strickland et. al., 1976).
In early embryonic development, as the blastocyst
expands, endoderm migrates from the inner cell mass (ICM)
to line the blastocoel.  This migration is along an
extracellular matrix (ECM) on the basal surface of the
trophectoderm.  Interactions between cells and components
of the ECM are essential for tissue differentiation and
regulation of embryonic growth (Mullins and Rohrlich,
1983).  In ovine embryos, PA production is elevated
through blastocoelic expansion, hatching and the period
corresponding to endodermal cell migration (Menino et
al., 1989).  In an effort to determine if PA is involved
in the mechanisms of endodermal migration, we
investigated the PA system and the effects of the
extracellular matrices type IV collagen, fibronectin and73 
laminin on the outgrowth of ovine inner cell masses in
vitro.
MATERIALS AND METHODS
EMBRYO COLLECTION AND CULTURE
Forty cross-bred ewes were estrous-synchronized with
cloprostenol sodium (Estrumate, Haver, Shawnee, KS) and
superovulated with porcine follicle stimulating hormone
(pFSH; Shering Corporation, Kenilworth, NJ).  Ewes
received two 100 Ag i.m. injections of cloprostenol
sodium 9 days apart (Day 0 = first cloprostenol sodium
injection) and twice daily injections of pFSH i.m. at
dosages of 4,  3 and 2 mg on Days 8, 9 and 10,
respectively for a total of 18 mg per ewe.  Estrus
detection was initiated 24 h after the second injection
of cloprostenol sodium and ewes were handmated by one of
3 rams starting at the onset of estrus and thereafter at
12-h intervals for as long as the ewe would except the
ram, or for a total of 3 matings.  Seven to 7.5 days
after onset of estrus, anesthesia was induced in ewes by
injection of 10 ml of 2.5% thiamylal sodium (Bio-tal;
Boehringer Ingelheim Animal Health, Inc., St. Joseph, MO)
into the jugular vein and was maintained during surgery
via inhalation of halothane (Flouthane, Fort Dodge, IA)
and oxygen.  The reproductive tract was exteriorized via
ventral midline laparotomy and the uteri were flushed in
a retrograde fashion with alpha Minimum Essential Medium74 
(MEM) buffered with N-2-hydroxyethyl piperizine-N'­
ethanesulfonic acid (MEM+H; Sigma, St. Louis, MO).
Uterine flushings were examined by means of a dissecting
microscope.  Morula to hatched blastocysts were recovered
from the uterine flushings by aspiration.  Embryos were
transferred to screw-cap tissue culture tubes containing
5 ml of MEM+H and 15 mg/ml bovine serum albumin
(MEM+BSA;Sigma) maintained at 39°C and transported to the
laboratory.  Embryos were recovered from the tubes,
washed three times in MEM+BSA,  and morphologically
evaluated using phase-contrast microscopy (200x).
Embryos were cultured overnight in groups of 1 to 10 in
50-gl microdrops of MEM+BSA under paraffin oil in a
humidified atmosphere of 5% CO2 in air at 39°C.
Conditioned medium was removed from the drops and stored
at -20°C until assayed for PA activity and evaluated for
inhibition by PA inhibitor-2 (PAI-2).
TROPHECTODERM AND INNER CELL MASS ISOLATION
For embryos which failed to complete the hatching
process during the overnight culture, zonae pellucidae
were removed using acidified PBS (pH 2).  Mechanical
separation of trophectoderm (TE) and inner cell mass
(ICM) tissues was performed by bissecting the blastocyst
using a finely drawn glass needle and a dissecting
microscope.  The glass needle was laid over the top of
the blastocyst and was positioned in a manner that would75 
confine the ICM to either the right or left half.  The
blastocyst was gently rolled as the needle was moved in a
sawing motion to separate the blastocyst into two
trophectodermal vesicles (TV).  The TV were washed in
MEM+BSA and returned to culture for 6-12 h to permit
resealing of the TE and re-expansion of the blastocoel
(Figure III-la and b).  Trophectodermal vesicles
possessing the ICM were subjected to immunosurgery using
the techniques of Carnegie and Cabaca (1991) and Solter
and Knowles (1975).  Embryos were sequentially incubated
in microdrops of rabbit anti-sheep antiserum (diluted 1
to 4 with MEM+BSA) for 1 h, three changes of MEM+BSA and
guinea pig complement (diluted 1 to 4 with MEM+BSA).  All
incubations were conducted at 39°C in a humidified
atmosphere of 5% CO2 in air.  Trophectodermal cells and
debris were removed by use of a siliconized micropipette,
and isolated ICM were placed in MEM+BSA until allocation
into appropriate treatment (Figure 111-2).  To estimate
the number of cells in an ICM at initiation of culture,
immediately after immunosurgical isolation 8 ICM were
washed twice in 2.0% sodium citrate, transferred to 0.7%
sodium citrate for 3 min., fixed on microscope slides
with 25% acetic acid in ethanol, air-dried (McGaughey and
Chang, 1969) and stained with hematoxylin and eosin.
EXPERIMENT 1
In Experiment 1, the effects of human plasminogen76 
(hPGN) and ECM-type on ICM and TE outgrowth were
evaluated.  Inner cell masses and TE were cultured in
glass, 8-chamber, Lab-Tek chamber slides (Nunc, Inc.,
Naperville, IL) coated with type IV collagen, fibronectin
or laminin (Sigma).  Chamber slides were coated by
overnight incubation with 150 Al of 10 µg /ml solutions of
type IV collagen, fibronectin or laminin in sterile PBS
with 1% antibiotic (Sigma).  The solutions were removed
the following morning and each well was rinsed three
times with MEM and then overlaid with MEM+BSA containing
0 or 150 µg /m1 hPGN (Sigma).  Inner cell masses and TE
were cultured for 72 h in a humidified atmosphere of 5%
CO2 in air at 39°C. At 24-h intervals ICM and TE were
observed for attachment and cellular outgrowth with an
inverted stage phase-constrast microscope and a
photomicrograph of each ICM was taken.  Numbers of cells
migrating away from the ICM core were also counted, and
length and width measurements of the ICM and outgrowth
were determined using an ocular micrometer.  At the end
of culture, medium was recovered and stored at -20°C
until assayed for PA and plasmin activity.  Areas of the
ICM and outgrowth were determined by tracing the
photomicrograph with a compensating polar planimeter
(model L-20-M, LASICO, Los Angeles, CA) and computing the
actual microscopic area.77 
EXPERIMENT 2:
Effects of PAI-2 or rabbit antiserum to bovine
urokinase-type PA (anti-uPA) on ICM outgrowth were
evaluated.  Previous work in our laboratory (Bartlett and
Menino, 1991) demonstrated that Day 7-11 ovine embryos
produced a urokinase-type PA (uPA) that was
immunoprecipitated with anti-uPA (American Diagnostica,
Inc., Greenwich, CT).  Because PAI-2 is the most
effective inhibitor of uPA (Hart and Rehemtulla, 1988) it
was also selected to suppress PA activity.  Inner cell
masses were cultured in 8-chamber, Lab-Tek chamber slides
coated with fibronectin as described in Experiment 1.
After overnight incubation, the slides were rinsed with
MEM and overlaid with MEM+BSA containing one of the
following: 0 or 100 IU/ml PAI-2 (American Diagnostica) or
10% normal rabbit serum (NRS) or anti-uPA (American
Diagnostica, Inc.).  Inner cell masses and their
outgrowth were evaluated at 24-h intervals and medium was
recovered at the end of culture as described in
Experiment 1.
EXPERIMENT 3:
The relationship between PA production and ECM-type
on ICM and TE outgrowth was evaluated.  Inner cell masses
and TE were cultured for 72 h on type IV collagen,
fibronectin, or laminin coated 60 x 15mm plastic tissue
culture dishes (Becton Dickinson and Company, Lincoln78 
Park, New Jersey).  Tissue culture dishes were coated by
aliquoting 16, 25-gl microdrops of collagen, fibronectin
or laminin onto the surface of the dish and covering the
drops with paraffin oil.  Dishes were incubated overnight
at 39°C in a humidified atmosphere of 5% CO2 in air.
Solutions were removed the following morning and each
drop was rinsed three times with MEM and overlaid with
MEM+BSA.  At 24-h intervals, 15 gl of conditioned medium
was removed from each microdrop, and replaced with 15 gl
of MEM+BSA.  Conditioned medium was placed in snap-cap
vials and stored at -20°C until assayed for PA activity.
CASEINOLYTIC ASSAYS FOR PLASMINOGEN ACTIVATOR AND PLASMIN
Plasminogen activator activities in conditioned
medium were analyzed using a caseinolytic-agar gel assay
as described for bovine embryos by Kaaekuahiwi and Menino
(1990).  Conditioned medium from PGN-containing cultures
were assayed for plasmin as described by Menino and
Willimas (1987).  Standards for the PA and plasmin assays
were human urokinase (E.C. 3.4.21.31; American
Diagnostica) and human plasmin (E.C. 3.4.21.7; Sigma),
respectively.
STATISTICAL ANALYSIS
All morphometric data were analyzed by multi-way
analysis of variance.  Differences in ICM and outgrowth
areas, cell numbers and PA production were tested for
significance by Duncan's multiple range test.79 
Correlation-regression analysis was performed on PA
production vs areas of 1CM, and outgrowth and cell
numbers.
RESULTS
Three hundred and thirty ova were recovered from 39
ewes.  Two hundred and fifteen embryos were considered
morphologically normal and used in the study.  Mean 
number of ovulations per ewe was 13.5 ± 1.1.  Mean number 
of cells per ICM was found to be 31.6 ± 2.8. 
EXPERIMENT 1 
Effects of plasminogen and ECM-type on ICM outgrowth
were examined.  Although cell numbers in outgrowths were
not significantly different, ICM cultured in 0 gg/ml
plasminogen grew to be larger (P<0.01) and had greater
(p<0.01) areas of outgrowth than those cultured in 150
mg/m1 plasminogen (table III-1, figure 111-3).  When
evaluated for main effects, fibronectin supported greater
areas of outgrowth and numbers of migrating cells
(P<0.01) than did either collagen or laminin (table III­
2).  While ICM area did not change (P>0.10), outgrowth
area and cell numbers increased (P<0.01; P<0.08,
respectively), with time (table 111-3).  When compared to
collagen and laminin, ICM cultured on fibronectin
produced low and intermediate levels of PA and plasmin,
respectively, however, no statistically significant
differences were observed (table 111-4).  Plasminogen80 
activator and plasmin activities for trophectodermal
vesicles are reported in table 111-5.  Trophectodermal
vesicles cultured on laminin produced high levels of PA.
EXPERIMENT 2
Plasminogen activator inhibitor-2 and rabbit anti-
bovine uPA were used to evaluate effects of inhibitors of
PA on ICM outgrowth on fibronectin.  Ability of PAI-2 to
inhibit PA activity is shown in figure 111-4.  When 100
IU/ml PAI-2 was incubated with conditioned medium, PA
activities were diminished (P<0.05).
Table 111-6 shows individual means over time of ICM
cultured in the presence or absence of PAI-2.  As a main
effect, addition of PAI-2 to the culture medium had no
effect (P>0.10) on ICM area (6,534.7  A2 vs 5,031.9 A2)  or
area of outgrowth (25,682.4 A2 vs 22,422.2 A2).  However,
those ICM cultured in 100 IU/ml PAI-2 had greater
(p<0.01) numbers of migrating cells than those cultured
with 0 IU/ml PAI-2 (33.9 vs. 17.0).  Individual means
over time of 1CM cultured in anti-uPA or NRS are
presented in table 111-7.  Anti-uPA had no effect on ICM
and outgrowth area, or cell number.  When analyzed for
main effects with time, ICM at 72 h were larger (p<0.05)
than those at 0 h (7,974 A 2 vs. 4,859.4 A 2 ).  When
compared to activities in 100 IU/m1 PAI-2 and 10% anti­
uPA, plasminogen activator activities were greater in
conditioned medium from ICM cultured in 0 IU/ml PAI-2 and81 
10% NRS, respectively (Table 111-8).
EXPERIMENT 3
The relationship between PA production and ECM-type
on ICM outgrowth was evaluated.  When analyzed by main
effects, ICM on fibronectin produced more (P<0.01) PA
(16.8 x 10-3 IU/d) than those cultured on collagen (1.5 x
10-3 IU/d) or laminin (2.9 x 10-3 IU/d).  Plasminogen
activator production on collagen, fibronectin and laminin
by time is presented in table 111-9.  Inner cell masses
cultured on fibronectin grew to be larger (P<0.05;
11,771.7 A2) than those on laminin (3,925.0 A2), but were
not different from those cultured on collagen (7,308.4
A2).  When analyzed by time, ICM area was largest
(P<0.05) at 48 h (13,273.1 p2), but not different
(P>0.05) from areas at 24 and 72 h (8,443.8 A2 and
10,219.7 A2 respectively). Area of outgrowth for ICM on
fibronectin was larger (p<0.01; 17,3347.3 A2) than those
cultured on laminin (no outgrowth) but not different
(P>0.05) from those on collagen (96,544.3 A2).  Outgrowth
at 72 h had larger area (242,844.6 A2; P<0.01) than at 0,
24 or 48 h (0 A2, 17,888.2 A2 and 99,122.7 A2,
respectively).  Number of cells that migrated on
collagen or fibronectin per day is presented in table
III-10.  When analyzed for main effects, no differences
(P>0.05) in number of cells migrating were found between
collagen and fibronectin (48.2 and 65.4, respectively).82 
Although PA production and outgrowth were highest for ICM
cultured on fibronectin, there was no correlation between
amount of PA produced and area of outgrowth (r=0.06;
P<0.01) or cell number (r=0.02; P<0.90) over all ECM
evaluated.  However, ICM area was correlated with PA
production (r=0.41; p<0.01).
This experiment also evaluated PA production by
trophectodermal vesicles cultured on collagen,
fibronectin or laminin.  No differences in PA production
were observed with respect to time or ECM (Table III-11).
DISCUSSION
Our results demonstrate that fibronectin enhances
outward migration of ovine ICM in vitro via a mechanism
independent of the PA system.  In previous reports,
fibronectin has been shown to support attachment and
outgrowth of mouse blastocysts (Armant et al., 1986) and
ICM (Carnegie and Cabaca, 1991).  In contrast to our
findings however, in those studies, laminin and/or
collagen supported equal if not greater amounts of cell
migration.  Although unclear, these differences in
affinity for collagen, fibronectin and laminin may be due
to species effects.  Reichert's membrane is a thick
basement membrane formed between the trophoblast and
parietal endoderm of mice and rats.  Using polyacrylamide
gel electrophoresis to analyze the structural components,
Smith and Strickland (1981) found Reichert's membrane to83 
be comprised mainly of the glycoproteins, collagen and
laminin with very low levels of fibronectin.  Although no
similar studies have been reported in sheep, it is
possible that a different combination of glycoproteins
exist in the ECM along which the ICM migrates.  In
agreement with our results, Coopman et al., (1991) found
that while fibronectin and collagen IV supported cellular
outgrowth, laminin arrested migration of a human breast
cell line.  The authors suggested that laminin functioned
as a stop signal for cell migration.  Results from the
present study support this hypothesis.  While fibronectin
and collagen both supported large amounts of outgrowth,
ICM cultured on laminin did not support outgrowth.
Addition of plasminogen to the culture medium
significantly reduced area of outgrowth.  Although Varani
et al. (1987) reported partial inhibition of attachment
and outgrowth of human tumor cell lines cultured on
fibronectin in the presence of plasminogen, because of
wide spread implication of PA having a role in cell
migration, these results were not expected.  Reich and
co-workers (1988) reported that malignant human and
murine cell lines are able to invade through basement
membrane via a protease cascade which results in the
breakdown of collagenase.  Using serine protease
inhibitors and antibodies to PA, inhibition of different
steps in the cascade reduced invasion of the tumor cells84 
through the basement membrane.  Similar results were
reported by Axelrod et al. (1989) when they observed that
transformed NIH 3T3 cells expressing PA can rapidly
invade a basement membrane.  This invasion was suppresed
with the addition of antibodies blocking the activity of
human PA.  Erikson and Isseroff (1989) reported neural
crest cells isolated from quail neural tubes produced
high levels of PA after 8 days in culture.  When added to
the culture medium, inhibitors of PA and plasmin
significantly reduced neural crest cell motility in vitro
supporting the hypothesis that proteases are important in
cell migration.  Interestingly, in contrast to these
results, Sanders and Prasad (1989) found that PA was not
involved in avian gastrulation, a period when epithelial
cells ingress and invade underlying tissue after
penetration through the basement membrane.  One possible
explanation for the inhibitory effects of plasminogen on
outgrowth is the levels of protease generated in the
cultures containing 150 µg /ml plasminogen may have been
too high.  This seems unlikely, however, because this
concentration resembles plasminogen concentrations
normally found in plasma (2 AM; Dano et al., 1985).
Further evidence against the involvement of the PA
system in ICM outgrowth is the observation that addition
of the PA inhibitors anti-uPA and PAI-2 had no effects on
outgrowth.  Previous reports from our laboratory show85 
rabbit anti-bovine uPA and anti-PAI-2 are effective
inhibitors of the uPA produced by ovine embryos (Bartlett
and Menino, 1991).  Although PAI-2 binds with greater
affinity to uPA, PAI-1 is also an effective inhibitor of
this PA.  Using PAI-1, Cajot et al., (1990) reported
PAI-1 regulated ECM breakdown by fibrosarcoma cells.
Addition of PAI-1 to culture medium inhibited matrix
degradation whereas antibodies against PAI-1 increased
it.  Additional studies need to be performed to examine
the effects of PAI-1 on outgrowth of isolated ovine ICM
before ruling out possible inhibition of ICM outgrowth by
inhibitors of PA.  Despite the observation that ICM
cultured on fibronectin produced more PA than ICM
cultured on collagen or laminin, PA production was not
correlated with outgrowth area or cell numbers in
outgrowths.  This suggests further that the mechanism of
endodermal migration in sheep occurs independent of
plasminogen activation.  However, additional work is
needed to determine why fibronectin supported greater PA
production.
Two events that are important in early embryonic
development are the migration of cells and remodelling of
the extracellular matrix.  Complex interactions occur
between migrating cells and the matrix constituents they
encounter during these processes.  Collectively, our
results suggest that the ECM, fibronectin, and to lesser86 
extent collagen, can support migration of endodermal
cells from isolated ovine ICM.  Although our data
strongly suggest that this migration occurs independently
of the PA system, further investigations using other
proteolytic systems need to be conducted to elucidate the
mechanism of endodermal migration in ovine embryos.87 
Figure III-la.  Trophectodermal vesicle containing
trophectoderm and inner cell mass after mechanical
microsurgery.
Figure III-lb.  Trophectodermal vesicle containing
trophectoderm only after mechanical microsurgery.88 
Figure 111-2.  Inner cell mass isolated immunosurgically.
-......89 
Figure 111-3.  Inner cell mass and accompanying outgrowth
after 48 h on Fibronectin.90 
Figure 111-4.  Inhibition of ovine embryonic plasminogen 
activator (PA) by PA inhibitor-2 (PAI-2). 
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Number of Embryos Table III-1. Overall means of ICM, outgrowth and total areas (42)
and numbers of migrating cells for ICM cultured in 0 or 150 µg /ml
plasminogen.
Level of
plasminogen  ICM area  Outgrowth area  Total area  Celli
µg /ml
0  5523.5'  16521.7a  21715.52  21.9a 
150  4408.4b  1732.5b  6066.8"  10. r 
a,b Values in the same column without common superscripts are
different (P<0.05).Table 111-2.  Overall means of ICM, outgrowth and total areas (A),
and numbers of migrating cells for ICM cultured on collagen,
fibronectin or laminin.
Extracellular
matrix  ICM area  Outgrowth area  Total area  Cell#
Collagen  5215.9°  1653.2'  6746.31  11.11 
Fibronectin  5749.6b  28841.7b  34081.9b  28.8b 
Laminin  4146.1'  11.91  4111.41  1.5' 
a,b Values in the same column without common superscripts are
different (P<0.05).Table 111-3.  Overall means of ICM, outgrowth and total areas (A2)
and numbers of migrating cells for 1CM at 0, 24, 48 and 72 h of culture.
Time  ICM area  Outgrowth area  Total area  Celli
0  5499.1'  0.0'  5499.1'
24  5103.3'  3169.7°)  8120.716  7.6'
48 4690.2'  17797.2"6c  22328.460  21.e
72  4157.3'  26922.4c  30499.6c  23.06
a,b,c Values in the same colum without common superscripts are
different (P<0.05).Table 111-4.  Plasminogen activator activities (IU/ml) and plasmin
concentrations (µg /ml) in conditioned medium from ovine inner cell
masses cultured for 72 h on collagen, fibronectin or laminin.
plasminogen activator  plasmin
Extracellular
matrix  n  mean + SE  n  mean + SE
Collagen  8  .653 ± 0.386'  7  1.25 ± 1.01'
Fibronectin  10  .133 ± 0.386  9  1.68 ± 0.89
Laminin  8  .442 ± 0.345  8  2.40 ± 0.95Table 111-5.  Plasminogen activator activities (IU/ml) and plasmin
concentrations (µg /ml) in conditioned medium from ovine trophectodermal
vesicles cultured for 72h on collagen, fibronectin or laminin.
plasminogen activator  plasmin
Extracellular
matrix  n  mean + SE  n  mean + SE
Collagen  7  0.152 ± 0.418`  7  1.83 ± 1.81`
Fibronectin  8  0.200 ± 0.391  9  5.13 ± 1.60
Laminin  9  0.924 ± 0.368  11  5.20 ± 1.45Table 111-6.  Individual mean inner cell mass (ICM), outgrowth and total
areas (p2) and cell numbers of ovine ICM cultured on fibronectin in medium
containing 0 or 100 IU/ml plasminogen activator inhibitor-2 (PAI-2).
PAI -2
0  IU/ml  100 IU/ml 
Area (x100)  0  24  48  72  0  24  48  72 
Inner cell mass 
and outgrowth  50.2  188.4  637.7  205.2  47.0  299.8  511.9  353.2 
Inner cell 
mass  50.2  51.9  58.3  40.9  47.0  70.6  48.7  95.0 
Outgrowth  0.0  140.9  579.4  176.6  0.0  244.3  473.7  309.4 
Cell number  11.0  21.3  19.0  37.9  38.7  25.1 Table 111-7.  Individual mean inner cell mass (ICM), outgrowth and
total areas (A2) and cell numbers of ovine inner cell masses cultured
on fibronectin in medium containing 10% rabbit antibovine urokinase-type
plasminogen activator serum (anti-uPA) or 10% normal rabbit serum (NRS).
10% NRS  10% anti-uPA
Area (x100)  0  24  48  72  0  24  48  72
Inner cell mass
and outgrowth  49.6  128.7  129.6  87.1  47.6  78.9  81.7  72.4
Inner cell
mass  49.6  57.6  63.7  87.1  47.6  59.2  62.8  72.4
Outgrowth  0.0  80.7  65.9  0.0  0.0  19.7  18.9  0.0
Cell number  0.0  37.0  11.0  2.5  0.0  6.0  16.0  0.0Table 111-8.  Mean plasminogen activator (PA) activities (IU/ml) in
conditioned medium from ovine inner cell masses containing PA inhibitor-2
(PAI-2) or rabbit anti-bovine urokinase-type PA serum (anti-uPA).
Treatment  n  Mean  S.E.
PAI-2
0 IU/ml  12  0.567*  0.253
100 IU/ml  14  0.069"  0.048
Anti-uPA
10%  7  0.012c  0.002
Normal rabbit
serum
10%  6  0.070d  0.016
a,b Values without similar superscripts are different (P<0.05).
c,d Values without similar superscripts are different (P<0.05).Table 111-9.  Mean plasminogen activator production (IUx103) by ovine inner
cell masses cultured in microdrops on collagen, fibronectin or laminin.
Time
Extracellular
matrix  n  24  48  72
Collagen  6  1.21  2.05  1.35
Fibronectin  6  11.09  16.45  22.92
Laminin  5  3.94  3.69  1.20100 
Table III-10.  Mean cell numbers in outgrowths generated
by ovine inner cell masses cultured in microdrops on
collagen or fibronectin.
Time
Extracellular
matrix  n  24  48  72
Collagen  6  7.7  42.0  94.8
Fibronectin  6  24.5  60.0  111.7101 
Table III-11.  Mean plasminogen activator production
(IU x 10 3 
)  by ovine trophectodermal vesicles cultured in
microdrops on collagen, fibronectin or laminin
Time
Extracellular
matrix  n  24  48  72
Collagen  6  12.8  28.6  10.2
Fibronectin  6  13.2  18.3  17.4
Laminin  6  15.2  8.7  19.8102 
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